New Monoclonal Antibody Drug One Step Closer to New Breakthrough

Some of the biggest pharma giants are coming together to drive the surge in the development of the next generation of antibodies. A new study on the monoclonal antibody therapy is one step closer to treating rare diseases. Analysts predict breakthroughs and research within this market will increase revenues to $140 billion in 2022.  

The US alone invests approximately $45 billion annually within the drug industry with the majority of research in biologics. Overall, the global pharmaceutical market at US$934.8 billion is predicted to be US$1.17trillion in 2021 thanks to innovate studies catalysed by R&D incentives.

Being so innovative and relying heavily on research and development, the pharmaceutical industry is closely intertwined with many discovery platforms including but not limited to:

  • Environmental Science
  • Physiology
  • Natural Science

Are you at the forefront of innovation?

Your company may be eligible for R&D Tax Credit, click here to find out more on how Swanson Reed can help.

 

Recommended Posts